413 related articles for article (PubMed ID: 9118815)
1. Choosing the right lipid-regulating agent. A guide to selection.
Farmer JA; Gotto AM
Drugs; 1996 Nov; 52(5):649-61. PubMed ID: 9118815
[TBL] [Abstract][Full Text] [Related]
2. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
Illingworth DR; Bacon S
Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
[TBL] [Abstract][Full Text] [Related]
3. Currently available hypolipidaemic drugs and future therapeutic developments.
Farmer JA; Gotto AM
Baillieres Clin Endocrinol Metab; 1995 Oct; 9(4):825-47. PubMed ID: 8593127
[TBL] [Abstract][Full Text] [Related]
4. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Schiel R; Bambauer R; Müller UA
Int J Artif Organs; 1995 Dec; 18(12):786-93. PubMed ID: 8964646
[TBL] [Abstract][Full Text] [Related]
5. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
6. Choice of cholesterol-lowering drugs.
Med Lett Drugs Ther; 1993 Mar; 35(891):19-22. PubMed ID: 8433674
[No Abstract] [Full Text] [Related]
7. Management of hypercholesterolaemia in postmenopausal women.
Davidson MH; Maki KC; Karp SK; Ingram KA
Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
[TBL] [Abstract][Full Text] [Related]
8. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
Brown WV
Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
[TBL] [Abstract][Full Text] [Related]
9. Current pharmacologic treatment of elevated serum cholesterol.
Tikkanen MJ; Nikkilä EA
Circulation; 1987 Sep; 76(3):529-33. PubMed ID: 3476221
[TBL] [Abstract][Full Text] [Related]
10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
11. Medical management of hyperlipidemia and the role of probucol.
Davignon J
Am J Cardiol; 1986 Jun; 57(16):22H-28H. PubMed ID: 3460320
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.
Farnier M
Am J Cardiovasc Drugs; 2003; 3(3):169-78. PubMed ID: 14727929
[TBL] [Abstract][Full Text] [Related]
13. Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
Hunninghake DB; Peters JR
Am J Med; 1987 Nov; 83(5B):44-9. PubMed ID: 3318453
[TBL] [Abstract][Full Text] [Related]
14. Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia.
Erkelens DW
Cardiology; 1990; 77 Suppl 4():33-8. PubMed ID: 2073670
[TBL] [Abstract][Full Text] [Related]
15. Lipid-lowering agents in proteinuric diseases.
Appel GB; Appel AS
Am J Nephrol; 1990; 10 Suppl 1():110-5. PubMed ID: 2256470
[TBL] [Abstract][Full Text] [Related]
16. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Adkins JC; Faulds D
Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
[TBL] [Abstract][Full Text] [Related]
17. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM
Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858
[TBL] [Abstract][Full Text] [Related]
18. Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Brown WV
Cardiology; 1989; 76 Suppl 1():45-51; discussion 52-4. PubMed ID: 2653623
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
20. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals.
Schectman G; Hiatt J
Am J Med; 1996 Feb; 100(2):197-204. PubMed ID: 8629655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
